Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types

Muntasir M. Majumder, Aino-Maija Leppä, Monica Hellesøy, Paul Dowling, Alina Malyutina, Reidun Kopperud, Despina Bazou, Emma Andersson, Alun Parsons, Jing Tang, Olli Kallioniemi, Satu Mustjoki, Peter O’Gorman, Krister Wennerberg, Kimmo Porkka, Bjørn T. Gjertsen, and Caroline A. Heckman

Disclosures: CAH has research funding from Celgene, Novartis, Orion Pharma and Oncopeptides, as well as the Innovative Medicines Initiative project HARMONY.

Contributions: MMM designed the work and wrote the manuscript. MMM, AML, MH, PD, RK and AP performed experimental work. MMM, AML, MH, AM and PD analyzed the data. BTG, JT, OK, POG, KP, SM and KW advised on the study. CAH supervised the study. All authors contributed to the writing and reviewed the manuscript.